Health Care and Biotech
Alcidion’s IT Targets Hospital Efficiency
Alcidion is an emerging operator in the field of hospital IT, with technology that can reduce deaths attributable to medical error. The stock price has doubled since it listed on ASX in February this year.
Dec 19 2016
Estia Health Beset By Uncertainty
Estia Health is beset by uncertainty surrounding the sustainability of earnings and this is not expected to moderate in the near term.
Dec 13 2016
Rebound For Sirtex
Michael Gable of Fairmont Equities suggests technically, Sirtex Medical should be set to recover.
Dec 13 2016
Sirtex Reaction Overdone
Increased competition has wedged dose sales for Sirtex Medical but brokers suspect the market’s reaction is overdone.
Dec 12 2016
Previous Stories
Top Ten Weekly Recommendation, Target Price, Earnings Forecast Changes
Dec 05 2011
Weekly update on recommendation, target price, and earnings forecast changes.
The Short Report
Nov 29 2011
FNArena’s weekly update on short positions in the Australian share market.
Top Ten Weekly Recommendation, Target Price, Earnings Forecast Changes
Nov 21 2011
Weekly update on recommendation, target price, and earnings forecast changes.
Top Ten Weekly Recommendation, Target Price, Earnings Forecast Changes
Nov 14 2011
Weekly update on recommendation, target price, and earnings forecast changes.
Prima Biomed And The Topic Of Cancer
Nov 10 2011
Nomura has initiated coverage on Prima Biomed with a Buy rating, attracted to the group’s potential to develop an immunotherapy-based treatment for ovarian cancer.
Treasure Chest: Impedimed Surprises
Nov 07 2011
FNArena’s Treasure Chest reports on money making ideas from stockbrokers and other experts. RBS Morgans sees plenty of upside following a surprise announcement by biotech company Impedimed.
Top Ten Weekly Recommendation, Target Price, Earnings Forecast Changes
Nov 07 2011
Weekly update on recommendation, target price, and earnings forecast changes.
Mesoblast: Undervalued Or Overvalued?
Nov 03 2011
While Bell Potter has long been a fan of Mesoblast’s stem cell technology, Macquarie initiates with an Underperform rating and argues the market has become over-excited.
Top Ten Weekly Recommendation, Target Price, Earnings Forecast Changes
Oct 31 2011
Weekly update on recommendation, target price, and earnings forecast changes.
ResMed Has Become A Post FY12 Story
Oct 26 2011
ResMed’s quarterly report disappointed many and broker responses have been mixed.
Analyse The Market From A Different Angle
Latest News
| 1 |
ASX Winners And Losers Of Today – 14-07-25Jul 14 2025 - Daily Market Reports |
| 2 |
Treasure Chest: CSL Not A One-Trick PonyJul 14 2025 - Treasure Chest |
| 3 |
ESG Focus: Infragreen & The Era of OpportunityJul 14 2025 - ESG Focus |
| 4 |
Australian Listed Real Estate Tables – 14-07-2025Jul 14 2025 - Weekly Reports |
| 5 |
The Global Impact Of Trump’s Copper TariffJul 14 2025 - Commodities |